Close Menu

NEW YORK ─ Sema4 said on Wednesday that it has secured approval from the New York State Department of Health to conduct its Sema4 Signal Whole Exome/Transcriptome Sequencing (WES/WTS) and PanCancer somatic tests.

The firm said it believes it is the first company with a commercial laboratory to be approved by the NYS DOH for WES/WTS for solid and hematologic malignancies using tumor-normal analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.